SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Abiomed, Inc. (ABMD) 当前追踪市盈率 (P/E) 为 127.9. 追踪盈利收益率为 0.78%.
本页证实的标准:
- VALUE (15/100, 未通过) — 追踪市盈率远高于标普500平均值约25，表明估值偏高 (P/E 127.9); 追踪盈利收益率低于10年期国债收益率（约4.3%），意味着债券提供更好的回报 (EY 0.78%).
- 追踪盈利收益率 0.78% — 低于债券收益率 — 投资者为预期增长而非当前盈利支付溢价。
SharesGrow 综合评分： 57/100 其中 3/7 项标准通过。
SharesGrow 7-Criteria Score
✗
价值
15/100
Price-to-Earnings & upside
Proven by this page
✓
健康
83/100
Debt-to-Equity & liquidity
→ Health
估值概览 — ABMD
估值倍数
P/E (TTM)127.9
前瞻 P/EN/A
PEG 比率N/A
前瞻 PEGN/A
P/B 比率0.00
P/S 比率16.94
EV/EBITDA0.0
每股数据
EPS (TTM)$2.98
每股账面价值$0.00
每股营收$22.49
每股自由现金流$0.00
收益率与内在价值
盈利收益率0.78%
股息收益率0.00%
P/E Ratio & Earnings Yield
每股收益 (EPS) 历史
| Year |
EPS（稀释） |
营收 |
净利润 |
净利润率 |
| 2013 |
$0.37 |
$158.12M |
$15.01M |
9.5% |
| 2014 |
$0.18 |
$183.64M |
$7.35M |
4% |
| 2015 |
$2.65 |
$230.31M |
$113.69M |
49.4% |
| 2016 |
$0.85 |
$329.54M |
$38.15M |
11.6% |
| 2017 |
$1.17 |
$445.3M |
$52.12M |
11.7% |
| 2018 |
$2.45 |
$593.75M |
$112.17M |
18.9% |
| 2019 |
$5.61 |
$769.43M |
$259.02M |
33.7% |
| 2020 |
$4.43 |
$840.88M |
$203.01M |
24.1% |
| 2021 |
$4.94 |
$847.52M |
$225.53M |
26.6% |
| 2022 |
$2.98 |
$1.03B |
$136.51M |
13.2% |
